(Q38843097)

English

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy

scientific article published on 24 May 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Frank C Passero

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Dimitra Grapsa

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Kostas N Syrigos

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Muhammad Wasif Saif

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

publication date

24 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Expert Review of Anticancer Therapy

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

697-703

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2016.1192471

21 January 2018

Identifiers

10.1080/14737140.2016.1192471

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38843097&oldid=1789799711"